26. A compound of structural formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

V and W are both N, or V and W are both CH;

Z is selected from CH and N, provided that when V and W are CH, then Z is not N;

R^1 is H, C_{1-3} alkyl, C_{1-3} alkoxy, F, or Cl;

R^2 is S(O)n R^6, COR^6 or CHO, wherein:

n is 0, 1 or 2, and

R^6 is $N(R^3)_2$ or C_{1-3} alkyl;

R^3 is independently H or C_{1-3} alkyl;

Ar is aryl or heteroaryl;

R^4 and R^5 are independently selected from:

(1) hydrogen,

(2) aryl, either unsubstituted or substituted with

(a) halo,

(b) C_{1-3} alkoxy,

(c)-$N(C_{1-3}$ alkyl$)_2$,

(d) C_{2-4} alkanoyl, or

(e) aryl,

(3) nitro,
(4) C_{1-5} alkyl,
(5) C_{1-5} alkoxy,
(6) hydroxy-C_{1-3} alkyl,
(7) carboxy,
(8) halo,
(9) C_{1-5} alkylthio,
(10) C_{1-5} ethoxycarbonyl,
(11) pyridylcarbonyl,
(12) benzoyl,
(13) phenyl-C_{1-3} alkoxy,
(14) pyridyl, either unsubstituted or substituted with C_{1-3} alkyl or C_{1-3} alkoxy,
(15) C_{3-6} cycloalkyl,
(16) oxazolyl,
(17) thiazolyl,
(18) triazolyl,
(19) phenoxy, and
(20) C_{2-6} alkanoyl.

27. The compound of Claim 26 wherein Z, V and W are N.

28. The compound of Claim 27 wherein Ar is phenyl, of structural formula I(a):



I(a)

or a pharmaceutically acceptable salt thereof.

29. The compound of Claim 28 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

30. The compound of Claim 29 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.

31. The compound of Claim 30 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)

or a pharmaceutically acceptable salt thereof.

32. The compound of Claim 31 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

33. The compound of Claim 32 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.

34. The compound of Claim 26 wherein Z is CH and both V and W are N.

35. The compound of Claim 34 wherein Ar is phenyl, of structural formula I(a):



I(a)

or a pharmaceutically acceptable salt thereof.

36. The compound of Claim 35 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

37. The compound of Claim 36 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.

38. The compound of Claim 37 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)

or a pharmaceutically acceptable salt thereof.

39. The compound of Claim 38 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

40. The compound of Claim 39 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.

41. The compound of Claim 26 wherein Z, V and W are CH.

42. The compound of Claim 41 wherein Ar is phenyl, of structural formula I(a):



I(a)

or a pharmaceutically acceptable salt thereof.

43. The compound of Claim 42 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

44. The compound of Claim 43 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.

45. The compound of Claim 44 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)

or a pharmaceutically acceptable salt thereof.

46. The compound of Claim 45 wherein R^2 is $-SO_2(C_{1-3}$ alkyl) or SO_2NH_2.

47. The compound of Claim 46 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl-C_{1-3} alkoxy, NO_2, C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxycarbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.

48. The compound of Claim 26 wherein R^2 is $-COR^6$ of structural formula I(d):



I(d)

or a pharmaceutically acceptable salt thereof.

49. The compound of Claim 48 or a pharmaceutically acceptable salt thereof selected from those depicted in the following Table:

R^6	
$-CH_3$	
$-CH_3$	
$-CH_3$	

50. A method of treating Y5 receptor mediated disease selected from the group consisting of obesity, anorexia nervosa, bulimia nervosa, diabetes, hypertension, hyperlipemia, hypercholesterolemia, congestive heart failure, renal dysfunction, sexual/reproductive disorders, depression, anxiety, epileptic seizure, memory loss, migraine, cerebral hemorrhage, nasal congestion, gastrointestinal disorders, and arthritis, which comprises administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Claim 26 that antagonizes the Y5 receptor.

51. The method of Claim 50 wherein the Y5 mediated disease is obesity.

52. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of claim 26.